Merck's Welireg receives FDA nod for expanded use with Lenvima in kidney cancer
read at Endpoints ↗ApprovalPositive
Merck announced that its drug Welireg has received FDA approval for use together with Eisai's Lenvima in patients with advanced renal cell carcinoma.
The clearance broadens the indication, allowing the combination to be prescribed to a larger group of kidney-cancer patients than previously approved.
Clinical data supporting the decision showed that the regimen improves outcomes for the targeted population.
The therapy will now be accessible to patients meeting the new criteria, representing a significant step for both companies.
source
This writeup was produced by pharmadog from original reporting by Endpoints.
Original headline: “Merck expands Welireg's use to broader set of kidney cancer patients”
read at Endpoints ↗82 words · retrieved Sep 25
comments(0)
5-min edit window · permanent after that